GCANRx Announces Relisting To OTCQB Market Tier

Rhea-AI Summary

Greater Cannabis Company (OTC: GCAN) announced that its common stock was approved for quotation on the OTCQB Venture Market effective December 3, 2025. To qualify, companies must meet higher financial and disclosure standards and follow best-practice corporate governance. The company says the move should provide enhanced investor benefits, including higher reporting standards, greater access to analyst coverage and news services, and more comprehensive compliance. The OTCQB is recognized by the SEC as an established public market for determining public market price for resale registrations.

U.S. investors can find current financial disclosure and Real-Time Level 2 quotes on otcmarkets.com. For investor inquiries visit gcanrx.com or contact info@gcanrx.com.

Positive

• Shares approved for quotation on OTCQB (December 3, 2025)
• Higher reporting standards and management certification
• Greater access to analyst coverage, news services and broker-dealer trading
• OTCQB recognized by the SEC as an established public market for resale pricing

Negative

• More comprehensive compliance requirements increase reporting obligations
• Requirement to meet high financial standards and governance may raise administrative burden

News Market Reaction – GCAN

-10.30%

1 alert

-10.30% News Effect

On the day this news was published, GCAN declined 10.30%, reflecting a significant negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Revenue: $0 Net loss (quarter): $36,099 Net loss (9M): $669,369 +5 more

8 metrics

Revenue $0 Q3 2025 per 10-Q

Net loss (quarter) $36,099 Q3 2025 per 10-Q

Net loss (9M) $669,369 Nine months ended Sep 30, 2025

Cash $21,355 As of Sep 30, 2025

Current liabilities $1,129,697 As of Sep 30, 2025

Stockholders’ deficit $(1,108,342) As of Sep 30, 2025

Reverse split ratio 1-for-1,500 Common stock reverse split in Oct 2025

Shares outstanding 900,256 Post-split share count noted in 10-Q

Market Reality Check

Price: $0.2474 Vol: Volume 205 is well below ...

low vol

$0.2474 Last Close

Volume Volume 205 is well below the 20-day average of 2,124 (about 0.1x normal activity) low

Technical Price 0.061 is far below the 200-day MA of 0.68 and close to the 52-week low of 0.0513

Peers on Argus

Peers show mixed moves: LVVV up 75%, TMSH down 50%, while CSTF, AGFAF, and VIBEF...

Peers show mixed moves: LVVV up 75%, TMSH down 50%, while CSTF, AGFAF, and VIBEF are flat. With GCAN up 1.67% and no peers in the momentum scanner, today’s setup appears stock-specific rather than a broad sector move.

Historical Context

1 past event · Latest: Jun 30 (Positive)

Pattern 1 events

Date	Event	Sentiment	Move	Catalyst
Jun 30	Market tier uplisting	Positive	+0.0%	Approval to uplist to OTCID Basic Market with higher governance standards.

Pattern Detected

Prior uplisting news produced no meaningful price reaction, suggesting governance/market-tier milestones have not yet driven strong trading responses.

Recent Company History

This announcement continues GCAN’s focus on market-tier upgrades and governance. In late June 2025, the company reported approval to uplist to the OTCID Basic Market, but the 24-hour price reaction was 0%. Since then, filings have highlighted a weak balance sheet, going-concern risks, and a major 1-for-1,500 reverse split that cut shares outstanding to about 900,256. Today’s relisting to the OTCQB tier fits that pattern of structural and listing-focused actions rather than operational milestones.

Market Pulse Summary

The stock dropped -10.3% in the session following this news. A negative reaction despite the OTCQB r...

Analysis

The stock dropped -10.3% in the session following this news. A negative reaction despite the OTCQB relisting would fit a pattern where structural milestones fail to offset financial strain. Recent filings reported $0 revenue, a quarterly net loss of $36,099, and cash of $21,355 versus significant current liabilities, with explicit going‑concern language and a 1-for-1,500 reverse split. These factors highlight balance-sheet and dilution risks that could dominate investor focus even when governance and market-tier news appears constructive.

Key Terms

otcqb, otcqb venture market, established public market, level 2 quotes, +2 more

6 terms

otcqb financial

"shares of its common stock were approved for quotation on the OTCQB"

OTCQB is a tier of the over‑the‑counter (OTC) market where smaller or developing companies list their shares for trading without being on a major stock exchange. Think of it like a well‑kept side street market: companies must meet basic reporting and transparency checks so investors get more information than the lowest OTC tier, but trading is usually less liquid and riskier than on big exchanges. Investors care because OTCQB listings can offer early access to growth stories but come with higher price swings and greater chance of limited resale options.

otcqb venture market financial

"approved for quotation on the OTCQB® Venture Market"

The OTCQB Venture Market is a tier of the over‑the‑counter (OTC) trading platform that groups early‑stage, smaller companies that do not meet the stricter requirements of higher OTC tiers. It gives investors a way to buy and sell shares in these higher‑risk, less mature firms with generally lower reporting and transparency standards; think of it as a marketplace’s “starter lane” where potential is available but uncertainty and volatility are higher, so investors should expect greater risk and do extra homework.

established public market regulatory

"considered by the Securities and Exchange Commission (SEC) as an “established public market”"

An established public market is a long-running, regulated place where shares and other securities are regularly bought and sold, such as major stock exchanges. For investors it matters because it usually offers reliable price information, rules protecting participants, and the ability to buy or sell quickly—like a busy, well‑known farmers' market where products are consistently available and prices are visible rather than a one‑time garage sale.

level 2 quotes technical

"U.S. investors can find current financial disclosure and Real-Time Level 2 quotes"

Level 2 quotes show the full list of buy and sell orders at multiple prices throughout the market, not just the single best bid and ask. For investors, this reveals how much supply and demand exists at different price points—useful for judging liquidity, spotting potential price moves, and placing or timing larger trades; think of it as seeing the entire checkout line instead of only the person next to the cashier.

forward-looking statements regulatory

"This press release contains certain forward-looking statements within the meaning of Section 27A"

Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.

section 21e of the securities exchange act of 1934 regulatory

"and Section 21E of the Securities Exchange Act of 1934"

Section 21E of the Securities Exchange Act of 1934 creates a legal safe harbor for forward-looking statements — projections, plans, estimates or predictions — made by public companies, provided those statements are identified as forward-looking and accompanied by meaningful cautionary language about risks and uncertainties. For investors, it matters because it helps distinguish promotional predictions from factual disclosures and signals which optimistic forecasts carry legal protection and which risks the company has warned could affect outcomes, like a weather forecast that comes with a disclaimer about changing conditions.

AI-generated analysis. Not financial advice.

Baltimore, Dec. 03, 2025 (GLOBE NEWSWIRE) -- The Greater Cannabis Company, Inc. (OTC: GCAN) (“the Company”), a clinical stage biopharmaceutical company focused on the development of new and effective cannabinoid therapeutics, today announced that shares of its common stock were approved for quotation on the OTCQB^® Venture Market. To qualify for this market, companies must meet high financial standards, follow best practice corporate governance, demonstrate compliance with U.S. securities laws and be current in their disclosure. The Company believes that the move to the OTCQB will provide enhanced investor benefits including higher reporting standards, greater access to analyst coverage and news services, and more comprehensive compliance requirements. The OTCQB is considered by the Securities and Exchange Commission (SEC) as an “established public market” for the purpose of determining the public market price when registering securities for resale with the SEC. The OTCQB dramatically increases transparency, reporting standards, management certification and compliance requirements. The majority of broker dealers trade stocks on the OTCQB. Historically this has resulted in greater liquidity and awareness for companies that reach the OTCQB tier.

To learn more, visit OTCQB. U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the Company on www.otcmarkets.com.

ENDS

For GCANRx Investor Relations inquiries visit www.gcanrx.com, or contact info@gcanrx.com. To receive the latest information about GCANRx sign up to the investor email at https://bit.ly/2ZNlBoj or follow @GCANRX on Twitter.

About Greater Cannabis Company: The Greater Cannabis Company (OTC: GCAN), (“GCANRx” or the “Company”) is a publicly traded clinical stage biopharmaceutical company focused on the development of new and effective cannabinoid therapeutics. The Company conducts medical research, and is pursuing clinical trials, to develop innovative cannabis-based treatments for various medical conditions and their symptoms with an initial focus on neuropsychiatric disorders. GCANRx’s mission is to bring its products to the global market for the benefit of patients seeking better solutions for their unmet medical needs.

Disclaimer: Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995. Statements in this press release that are not strictly historical are “forward-looking” statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. These statements involve a high degree of risk and uncertainty, are predictions only and actual events or results may differ materially from those projected in such forward-looking statements. Factors that could cause or contribute to differences include the uncertainty regarding viability and market acceptance of the Company’s products and services, the ability to complete development plans in a timely manner, changes in relationships with third parties, product mix sold by the Company and other factors described in the Company’s most recent periodic filings with the Securities and Exchange Commission, including its 2020 Annual Report on Form 10-K and quarterly reports on Form 10-Q.

Forward-Looking Statements: This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company's product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions.

These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential, "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Contact: The Greater Cannabis Company, Inc.
443-738-4051
info@gcanrx.com
www.gcanrx.com

FAQ

What did Greater Cannabis Company (GCAN) announce on December 3, 2025?

The company announced its common stock was approved for quotation on the OTCQB Venture Market.

How does GCAN’s move to the OTCQB affect investor information and transparency?

The move brings higher reporting standards, management certification, and more comprehensive disclosure requirements.

Will GCAN shares be available for real-time quotes after the OTCQB relisting?

Yes; U.S. investors can find current financial disclosure and Real-Time Level 2 quotes on otcmarkets.com.

Does the OTCQB designation help when registering GCAN securities for resale with the SEC?

Yes; the OTCQB is considered an established public market by the SEC for determining public market price for resale registrations.

What investor benefits did GCAN cite for moving to OTCQB on December 3, 2025?

The company cited greater analyst coverage, improved news distribution, higher reporting standards, and broader broker-dealer trading.